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Transcription factor Phox2 upregulates expression of
norepinephrine transporter and dopamine β-hydroxylase in adult
rat brains
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Abstract
Degeneration of the noradrenergic locus coeruleus (LC) in aging and neurodegenerative diseases
is well documented. Slowing or reversing this effect may have therapeutic implications. Phox2a
and Phox2b are homeodomain transcriptional factors that function as determinants of the
noradrenergic phenotype during embryogenesis. In the present study, recombinant lentiviral
eGFP-Phox2a and -Phox2b (vPhox2a and vPhox2b) were constructed to study the effects of
Phox2a/2b over-expression on dopamine β-hydroxylase (DBH) and norepinephrine transporter
(NET) levels in central noradrenergic neurons. Microinjection of vPhox2 into the LC of adult rats
significantly increased Phox2 mRNA levels in the LC region. Over-expression of either Phox2a or
Phox2b in the LC was paralleled by significant increases in mRNA and protein levels of DBH and
NET in the LC. Similar increases in DBH and NET protein levels were observed in the
hippocampus following vPhox2 microinjection. In the frontal cortex, only NET protein levels were
significantly increased by vPhox2 microinjection. Over-expression of Phox2 genes resulted in a
significant increase in BrdU-positive cells in the hippocampal dentate gyrus. The present study
demonstrates an upregulatory effect of Phox2a and Phox2b on the expression of DBH and NET in
noradrenergic neurons of rat brains, an effect not previously shown in adult animals. Phox2 genes
may play an important role in maintaining the function of the noradrenergic neurons after birth,
and regulation of Phox2 gene expression may have therapeutic utility in aging or disorders
involving degeneration of noradrenergic neurons.
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The major source of norepinephrine in brains is the locus coeruleus (LC), from which
noradrenergic neurons project to numerous areas including the hippocampus and frontal
cortex. Noradrenergic neurons exclusively express dopamine β-hydroxylase (DBH, EC
1.14.2.1), which converts dopamine to norepinephrine (Kaufman and Friedman, 1965), and
the norepinephrine (NE) transporter (NET), a membrane protein which transports NE into
noradrenergic neurons (Barker and Blakely, 1995). Their specific expression makes DBH
and NET as the markers of noradrenergic neurons (Valarche et al., 1993, Lorang et al., 1994,
Comer et al., 1998, Schroeter et al., 2000). The expression of DBH and NET is also tightly
bound to the propagation and function of noradrenergic neurons. For example, substantial
loss of LC neurons has been identified in aging, Parkinson’ disease (PD), and Alzheimer’s
disease (AD) (Zarow et al., 2003). As a direct consequence of the LC neuron loss, the
expression of DBH and NET is proportionately reduced in advancing age (Chan-Palay and
Asan, 1989, Tejani-Butt and Ordway, 1992), PD (Nagatsu and Sawada, 2007) and AD
(Iversen et al., 1983).
Phox2a and Phox2b are two closely related homeodomain transcription factors with similar
expression patterns. They play a critical role as determinants for the development of
noradrenergic neurons during embryogenesis. For example, inactivation of the Phox2 genes
in mice leads to the agenesis of the LC (Morin et al., 1997), disruption of noradrenergic
differentiation and failed phenotype expression (Pattyn et al., 1999, Pattyn et al., 2000). It
has been reported that while Phox2a expression is maintained through life, that of Phox2b is
substantially reduced. Recent study demonstrated that loss of one Phox2 protein can be fully
compensated by expression of the other (Coppola et al., 2010). However, whether these
genes still have modulatory effects on noradrenergic neurons and phenotypes in adult brains
has not been elucidated. Our previous in vivo study showed that a significant reduction in
mRNAs of NET and DBH in the LC and adrenal glands of aging rats was paralleled with a
decline in mRNA levels of Phox2 (Zhu et al., 2005), suggesting a possible relationship
between these marker genes and Phox2 genes in noradrenergic neurons after birth.
Furthermore, in vitro investigations (Yang et al., 1998, Stanke et al., 1999, Kim et al., 2002,
Fan et al., 2009) demonstrated direct transcriptional activation of DBH and NET genes by
Phox2 genes. Collectively, these findings implicate the possible modulatory effect of Phox2
genes on the expression of NET and DBH after birth. Given that the cellular mechanisms
and potential therapeutic implications of LC neuronal loss in aging and neurodegeneration
diseases remain unknown, exploring this modulation may provide important insight for
better management of these diseases.
In the present study, we sought to test the hypothesis that Phox2a and Phox2b genes are able
to upregulate the expression of NET and DBH after birth. Recombinant lentiviral eGFP-
Phox2 and -Phox2b (vPhox2a and vPhox2b) were microinjected into the LC of adult rats.
We observed that forced over-expression of Phox2a and Phox2b in the rat LC markedly
influence the expression of NET and DBH in noradrenergic neurons. The present study
suggests that Phox2a and Phox2b possess modulatory roles in the control of the expression
of NET and DBH in adult animal brains.
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cDNA cloning of rat Phox2a/2b
Total RNA was prepared from the LC area and adrenal glands of Fischer 344 rats using
TRIzol reagent (Invitrogen, Carlsbad, CA) as per manufacturer’s instructions. Full-length
cDNAs encoding Phox2a and Phox2b were prepared by RT-PCR using these total RNA
samples. The following primers were used for Phox2a (NM_053869; forward primer, ACG
CGT CGA CC ATG GAC TAC TCC TAC CTC AAT TCG; reverse primer, TGT CTA
GAG CGG CTA GAA GAG GTT TGTC) and for Phox2b (XM_344239; forward primer,
ACG CGT CGA CC ATG GAC TAC TCC TAC CTC AAT TCG; reverse primer; TGT
CTA GAT CAG AAC ATA CTG CTC TTC ACT AAG). Annealing temperatures of 62°C
and 51°C for Phox2a and Phox2b, respectively, were required for optimal amplification.
Amplified fragments were gel purified using QIAEX II beads according to the
manufacturer’s instructions (Qiagen, Valencia, CA) and cloned into the SalI/Xba of the
pCMV Sport 6 expression vector (Invitrogen, NY). Construct identity was confirmed by
DNA sequencing.
Cell cultures
The cell types used in the present study were human embryonic kidney (HEK) 293T (ATCC
#CRL-11268), 293FT cells (Invitrogen R700-07), human fibrosarcoma cells HT1080
(ATCC #CCL-121) and rat PC12 (ATCC #CRL-1721.1). HEK293T, 293FT and HT1080
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
200 mM L-glutamine, 10 mM MEM non-essential amino acids, 100 mM MEM sodium
pyruvate and G418 (500 μg/mL). PC12 cells were maintained in RPMI 1640 medium. All
these media were also supplemented with 10% heat-inactivated fetal bovine serum (FBS),
penicillin (100 U/mL), and streptomycin (100 μg/mL), at 37°C in humidified air containing
5% CO2.
Lentiviral vector production
The preparation and use of all viral vectors were carried out in a bio-safety level 2
laboratory with the approval of the Institutional Biosafety Committee of the East Tennessee
State University. All reagents and kits were purchased from Invitrogen (Carlsbad, CA).
Lentiviral-mediated expression cassettes, with dual promoters to drive the gene of interest
(Phox2a or Phox2b), and the reporter gene (enhanced green fluorescent protein, eGFP)
which allows direct observation of viral delivery to the LC site, were constructed according
to the manufacturer’s instruction. One cassette containing eGFP alone was used as a control
in the experiments. Briefly, cDNAs of eGFP and rat Phox2a or Phox2b were modified using
PCR to include the sequence CACC at the 5′ end, in order to be complimentary to the
overhang sequence GTGG in the pENTR/D-TOPO vector. These cDNAs were inserted into
the pENTR/D-TOPO vector and the produced cDNA-vectors were further transferred into a
lentiviral plasmid pLenti6/V5-DEST by LR-clonase. The identity of the recombinant
expression vector pLenti6/V5-eGFP-Phox2a (or 2b) was confirmed by restriction analysis,
PCR reaction, and sequencing. Recombinant expression cassettes were finally produced by
co-infection of HEK293T cells with the recombinant expression vector pLenti6/V5-eGFP-
Phox2a (or 2b) and packaging vectors, pCMVΔR8.9 and pVSVG, using the TransIT®-293
Transfection Reagent. A lentiviral stock was produced and satisfactory eGFP expression
was verified by fluorescence microscopic analysis by fluorescence-activated cell sorter
(FACS) analysis. Lentiviral supernatant was harvested 72 h post-infection after microscopic
verification of fluorescence and filtered through a 0.45 μM membrane. The non-
concentrated virus titer was greater than 5×106 TU/ml. High-titer viral stocks were obtained
by untracentrifugation at 25,000 rpm for 2 h and the viral pellet was reconstituted overnight
(4°C) in artificial cerebrospinal fluid (aCSF). Viral titers were determined by infecting
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HT1080 cells. The cells were plated at a density of 1×105 cells per well in six-well tissue
culture dishes. Serial dilutions of the vector stock were added, and blue-stained colonies
were counted to determine the titer after blasticidin was added for colony screening. Viral
stocks were stored at −80°C until use.
Animal and in vivo stereotaxic microinjection
Male Fischer 344 rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 220-250 g at the
time of initiation of experiments were housed on a 12 h light/dark cycle and with food and
water provided ad libitum. All animal procedures were approved by the East Tennessee
State University Animal Care and Use Committee and complied with the NIH Guide for the
Care and Use of Laboratory Animals. After an acclimation period of 5 days, rats were
randomly assigned to the experimental and placebo groups. Microinjection was performed
following previously published procedures (Carlezon Jr. and Neve, 2003) with
modifications. Briefly, using a stereotaxic apparatus (David Kopf Instruments, Tujunga,
CA), two burr holes for bilateral injection (1 mm in diameter) were drilled to the level of the
dura in the skull according to the coordinates of the LC. Hamilton syringes (30 gauge
beveled needle) loaded with recombinant lentiviruses were lowered to the LC ([AP]= −10.0
mm, [LAT]= ±1.3 mm, and [V]= −6.0 mm) (Paxinos and Watson, 2005). Once at the
desired depth, microinjections of vector constructs (2 μl at 1×108 TU of titer per milliliter)
were delivered into the LC region at a rate of 0.1 μl/30 seconds over a period of 10 minutes.
The microinjection volume of 2 μl for viral vectors is a widely used parameter from
previous reports (Carlezon et al., 1998, Azzouz et al., 2002, Carlezon Jr. and Neve, 2003).
To allow maximum diffusion from the microinjector tip and absorption in the tissue, the
syringe needle was kept in the injection place for additional 5 min, then withdrawn very
slowly. The skull holes were sealed with dental cement to prevent cerebrospinal fluid loss.
The incision was closed with sutures and covered with antibiotic ointment. Some rats were
bilaterally microinjected with lentiviral cassette carrying eGFP only as the control, while
some were sham-operated (the injection syringe is lowered into the LC region without
injection) to rule out possible effects of the surgery. Rats were allowed to recover, following
which they were sacrificed on the designated day as described in Results. Microinjection
into the LC region was verified by examining eGFP fluorescence under a fluorescence
microscope to confirm the delivery of the viruses to the LC region.
In situ hybridization
After euthanized, rat brains were removed, rapidly frozen in 2-methyl-butane on dry-ice, and
then stored at −80° C until sectioning. Sections (16 μm) through the pontine LC region were
cut on a cryostat, mounted on SuperFrost Plus slides (Fisher Scientific; Pittsburg, PA), and
stored at −80° C. On the day of hybridization experiment, slides were fixed with 4% (w/v)
paraformaldehyde followed by acetylation with acetic anhydride. Lipids were extracted by
washing with increasing concentrations of alcohol (50, 70, 95 and 100% [vols]). [35S]-
labeled cRNA probes (Perkinelmer, MA) were transcribed in vitro from cDNAs for rat
Phox2a (0.85 kb), Phox2b (0.95 kb), NET (0.5 kb), and DBH (1.4 kb) in pGEM-3Zf vectors
with T3 or T7 RNA polymerase. Pre-hybridized sections were incubated with a
hybridization solution containing the radiolabeled probes, at 55° C for 3-5 h. The brain
tissue sections were then washed extensively and apposed to Biomax autoradiographic films
(Kodak; Rochester, NY). For higher resolution studies, sections were also dipped in Kodak
NTB2 emulsion (Fisher, Pittsburgh, PA) and quantitatively analyzed with the MCID CORE
7.0 program (Imaging Research Inc.; Linton, England).
Detection of protein levels
Protein levels of Phox2a/b, NET, and DBH in cultured cells (for in vitro experiments), or rat
hippocampus and frontal cortex from rats were determined by Western blotting. These
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samples were homogenized in sample buffer containing sodium lauryl sulfate (SDS) and β-
mercaptoethanol. After centrifugation at 1000 xg, protein concentrations of supernatants
were measured using the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Equal amounts of
samples (10 μg of protein per lane) were loaded on 10% SDS-polyacrylamide gels for
electrophoresis and transferred by electro-blotting to a polyvinylidene diflouride membrane.
The membranes were incubated overnight at 4°C with primary antibodies [either anti-
Phox2a or Phox2b from rabbit (1:200 dilution, Sigma-Aldrich, St. Louis, MO), anti-NET
from rabbit (1:330 dilution; Alpha Diagnostic Intl. Inc, San Antonio, TX), or anti-DBH from
rabbit (1:400 dilution; Santa Cruz Biotechnology Inc., CA). Membranes were then washed
and incubated with secondary antibodies (horseradish peroxidase-conjugated anti-rabbit
IgG, 1:3000; Amersham Biosciences, Little Chalfont, UK). Immunoreactive bands were
visualized by enhanced chemiluminescence (ECL, Amersham; Piscataway, NJ). Bands were
detected by the Kodak Image station (New Haven, CT), or exposed on films and scanned by
Quantity One imaging devices (Bio-Rad, Hercules, CA). Band densities were quantified
using imaging software (Molecular Dynamics IQ solutions, Molecular Dynamics, Inc.,
Sunnyvale, CA). A linear standard curve was created from optical densities (ODs) of bands
with a dilution series of total proteins prepared from 293-FT, PC12 cells, or brain tissues.
OD values of Phox2, NET, and DBH signals were compared and normalized with β-actin
immunoreactivities, which were determined on the same blot. Normalized values were then
averaged for all replicated gels and used to calculate the relative changes on the same gel.
Immunofluorescence staining with NET and DBH
For the immunofluorescence staining experiments, rats were transcardially perfused under
anesthesia with pentobarbital (40mg/kg, i.p.) using 4% paraformaldehyde in 0.1 mol/L
phosphate buffer, pH 7.4. Brains were stored in 10% sucrose followed by 30% sucrose and
then sectioned at 30 μm using a sliding microtome. Immunofluorescence staining was
performed using commercial monoclonal antibodies from mice to NET (MAb Technologies,
Inc., TN), and polyclonal antibody from rabbit against DBH (Protos Biotech Corp, New
York, NY). Brain sections were washed three times in phosphate-buffered saline (PBS) and
preincubated in 5% bovine serum albumin in PBS supplemented with 0.2% Triton-X 100 for
1 h at room temperature, followed by incubation in primary antibody (1:500 dilution, in PBS
containing 0.2% Triton-X 100) overnight at 4° C. After washing, sections were then
incubated with secondary antibodies (for NET: Alexa Fluor 488-conjugated goat anti-mouse
IgG; for DBH: Alexa Fluor 488-conjugated goat anti-rabbit IgG; all from Invitrogen,
Carlsbad, CA) for 2 h at room temperature, followed by 4 rinses with 0.1M PBS. Slides
were then covered by coverslips using Citifluor mounting medium. In order to reduce inter-
animal staining variability, each immunofluorescence staining experiment was performed on
all tissue sections at the same time by an investigator blinded to the animal group.
Immunofluorescence labeling was observed and acquired under a Leica TCS SP2 confocal
microscope system (Leica Microsystems Inc., Bannockburn, IL, USA). Images were
semiquantitatively analyzed by using ImageJ software (Rasband, US National Institutes of
Health, Bethesda, http://rsbweb.nih.gov/ij, 2010). Reference background levels were
obtained from non-immunoreactive portions of brain sections adjacent to the LC region by
determining the optical density on a 0 to 255 grayscale (0 being white and 255 black). The
area fraction of immunofluorescence was quantified at three levels of each section and two
sections from each rat.
5-Bromo-2-deoxyuridine (BrdU) injection, tissue collection and processing
BrdU immunohistochemical staining was used for the detection of newly generated cells in
the dentate gyrus (DG) of the hippocampus. This experiment was performed in rats that
were in vivo stereotaxically microinjected with vPhox2 for 21 days. BrdU (100 mg/kg/day,
Sigma-Aldrich, St. Louis, MO) was intraperitoneally injected once daily for 5 successive
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days starting on day 15 after administration of vPhox2. Rats were perfused 24 h after the last
injection. Serial sections (30 μm) were cut through the rostral/caudal extent of the
hippocampus (bregma −1.88 mm to −5.20 mm) (Paxinos and Watson, 2005) using a sliding
microtome. Every sixth section was coded and stored in the long-term storage solution
(sucrose/ethylene glycol/sodium azide in PBS) at −20°C.
For BrdU labeling, these free-floating sections were washed 3 times in PBS and 2xSSC, and
then incubated in 50% formamide-2x standard saline citrate at 65°C for 2 h. Following
denaturation in 2 N HCl at 37°C for 30 min, the sections were washed in 2xSSC and PBS,
preincubated in 1% Triton-X/4% goat serum/PBS, and then incubated overnight at 4°C with
a BrdU-specific mouse monoclonal antibody (1:600; Sigma-Aldrich). The next day, sections
were incubated for 1 h with a biotinylated mouse secondary antibody (1:200; Vector
Laboratories, Burlingame, CA. U.S.A.), followed by another 1 h incubation with
VECTASTAIN (Elite ABC Kit, 1:100; Vector Laboratories). Cells were visualized with
3,3′-diaminobenzidine containing nickel chloride (nickel-DAB; 40 mg/mL).
Quantitation of BrdU-positive cells was performed at 400x and 1000x magnifications under
a light microscope (Zeiss Axio Observer Z1, Carl Zeiss Microimaging, LLC, Jena,
Germany) using a modified unbiased stereology protocol (Eisch et al., 2000, Malberg et al.,
2000). BrdU-positive cells were counted in the granule cell layer (GCL) and subgranular
zone, which was defined as a two-cell body-wide zone along the border of the GCL. The
total number of BrdU-positive cells was calculated by multiplying the cell number counted
in each 6th section by 6 and reported as cells per DG.
Statistics
All experimental data are presented in the text and graphs as the mean ± SEM. Data were
analyzed by one way analysis of variance (ANOVA, SigmaStat, Systat Software Inc.,
Richmond) when multiple treatment groups were compared. A post-hoc Student-Newman-
Keuls test was performed for further examination of group differences.
RESULTS
cDNA cloning of rat Phox2a/2b
Sequence analysis of the cloned cDNAs of rat Phox2 revealed an open reading frame of 846
base pairs for rat Phox2a, implicating a protein consisting of 281 amino acids; and 945 base
pairs for rat Phox2b, implicating a protein consisting of 314 amino acids. At the nucleotide
level, rat Phox2a and mouse Phox2a share 97% identity, while rat Phox2a and human
Phox2a show 90% identity (data not shown). In the deduced amino acid sequences, rat
Phox2a possesses 98.9% and 79.6% identity to its mouse and human counterparts
respectively (Fig. 1). Similarly, rat Phox2b and mouse Phox2b share 95% identity of the
nucleotide, while rat Phox2b and human Phox2b show 91% identity (data not shown). For
the deduced amino acid sequences, rat Phox2b possesses 100% identity to its mouse and
human counterparts respectively. It is noteworthy that the nucleotide sequence of our cloned
rat Phox2b cDNA is exactly the same as that of the ORF of predicted rat Phox2b in the
Genebank (XM_344239.2, GI:62660435). The cloned rat Phox2 cDNAs provide the
opportunity to investigate the effects of microinjection of Phox2 cDNAs on the expression
of noradrenergic phenotypes in adult rats.
Lentivirus-mediated expression of Phox2 in 293FT and PC12 cells
To test the infection efficiency of the vPhox2 in vitro, 293FT cells were infected with a
lentiviral stock for 72 hours. As shown in Fig. 2A, GFP was found to be expressed in 91%
of cells as measured by a fluorescence-activated cell sorter (FACS, see description in the
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legend of Fig. 2A). Next, the ability of the expression cassette to induce expression of
transgenes in vitro was confirmed following transduction of PC12 cells with vPhox2a or
vPhox2b at 1:2, 1:4, 1:8, 1:16 and 1:32 dilutions of non-concentrated lentiviral stocks with
the viral titer (TU/ml) for vPhox2a: 4×105 and for vPhox2b: 5×106. The reason to use non-
concentrated lentiviral stock in vitro tests is based on the consideration that concentrated
lentivirus preparations are mainly used for in vivo experiments for the sake of using a
relatively small volume (2 μl). Three days later, cells were harvested. Western blotting for
Phox2a or Phox2b showed that the vPhox2a and vPhox2b significantly increased protein
levels of Phox2a and Phox2b in a concentration-dependent manner (Figs. 2B, 2C;
F5,30=2.87, p < 0.05 for vPhox2a; F5,30=5.51, p < 0.01 for vPhox2b). These in vitro
expression tests demonstrated that transduction with the vPhox2 significantly increased
levels of Phox2 proteins, indicating that a relatively high titer lentiviral packaging platform
was preliminary established. We then examined overexpressed Phox2 on protein levels of
DBH in the same cell preparations. Transduction of the vPhox2a or vPhox2b markedly
enhanced protein levels of DBH (F5,30=4.83, p < 0.01 for vPhox2a; F5,24=4.45, p < 0.01 for
vPhox2b). Post hoc tests showed that the vPhox2a preparation at the dilution of 1:8, 1:4 and
1:2 increased DBH proteins by 89%, 129% and 105%, respectively (all p<0.05). Similarly,
the vPhox2b preparation at the dilution of 1:4 and 1:2 increased DBH protein levels by 85%
and 69%, respectively (all p<0.05, Figs. 2D and 2E). These results are consistent with our
previous report in which transfection with cDNAs of human Phox2a or Phox2b significantly
increased expression of DBH in vitro (Fan et al., 2009).
Microinjection of vPhox2 increased mRNA levels of NET and DBH in the LC region
To test effects of over-expression of Phox2 genes in the LC region on the expression of the
noradrenergic phenotype in the same area, we stereotaxically microinjected the vPhox2
(about 1×108 TU/ml) into the bilateral LC region of rats. All rats were euthanized on days 7,
14 and 21 after injection. Fig. 3A shows that the vPhox2 was accurately delivered to the LC
region, as there is clear GFP fluorescence in the target area. Rats with missed placements
were eliminated from further experiments. We then performed ex vivo in situ hybridization
to measure mRNA levels of Phox2a and Phox2b in the LC region. As shown in Figs. 3B and
4, microinjection of vPhox2a or vPhox2b significantly affected mRNA levels of Phox2 in
the rat LC (F4,75=11.95, p < 0.001 for vPhox2a; F4,60=4.95, p < 0.05 for vPhox2b). Post hoc
contrasts revealed that there were no significant differences between the control and sham
groups in the expression of Phox2a and Phox2b genes, demonstrating no effect of surgery.
Likewise, there was a consistent lack of differences in expression levels of noradrenergic
phenotypes comparing control and sham groups for all following experiments, and this is
not mentioned again. Compared to the control group at the same time points, Phox2a mRNA
levels were robustly increased 119%, 146 and 141%, on days 7, 14 and 21 (all p<0.01),
respectively, after microinjection of vPhox2a. Levels of Phox2b mRNA in the LC region
were significantly increased by 41% (P<0.05) 21 days after microinjection with vPhox2b, as
compared to those of the control group. Although there was a trend towards an increase for
Phox2b mRNA on days 7 and 14 (by 23% and 20%, respectively) after microinjection of
vPhox2b, these increases did not reach significance (Fig. 4). Nevertheless, these experiments
demonstrated that microinjection of vPhox2 resulted in over-expression of these genes in the
LC region.
To examine biological effects of over-expressed Phox2a and Phox2b in the LC region on
noradrenergic phenotypes, we measured mRNA levels of DBH and NET in the LC region in
the same rats used for the measurement of Phox2 mRNAs. As shown in Fig. 5,
microinjection of vPhox2a or vPhox2b significantly influenced mRNA levels of DBH in the
LC region (F4,65=11.74, p < 0.001, for microinjection of vPhox2a; F4,70=10.48, p<0.001,
for microinjection of vPhox2b). Further comparison revealed that DBH mRNA levels were
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increased by 57% (p<0.01), 42% (p<0.05) and 66% (p<0.01), respectively, on days 7, 14
and 21 following microinjection of vPhox2a. Similarly, 21 days after microinjection of
vPhox2b, DBH mRNA levels in the LC region were significantly increased by 57%
(p<0.01). Interestingly, although Phox2b mRNA levels were only modestly increased 7 and
14 days after microinjection of vPhox2b (Fig. 4), DBH mRNA levels were significantly
increased by 39% (p<0.05) and 66% (p<0.01) during the same period.
Microinjection of vPhox2a or vPhox2b also markedly affected mRNA levels of NET
(F4,60=4.44, p < 0.01, for microinjection of vPhox2a; F4,70=8.92, p<0.01, for microinjection
of vPhox2b; Fig. 6). NET mRNA levels in the LC were increased by 78% (p<0.05) 14 days
after microinjection of vPhox2a. Small increase in NET mRNA levels was observed 7 (by
39%) and 21 (by 35%) days after microinjection of vPhox2a, but these increases did not
reach statistical significance when compared with the control (both p>0.05). Comparatively,
microinjection with vPhox2b has stronger effects than vPhox2a on NET mRNA in the LC.
As shown in Fig. 6, NET mRNA levels in the LC were significantly increased 7, 14 and 21
days after microinjection by 111%, 139% and 68% (all p<0.01), respectively, compared to
that of the control group.
Microinjection of vPhox2 increased protein levels of DBH and NET in the LC region
DBH and NET protein levels were examined 21 days after microinjection by
immunofluorescence staining. As shown in Figs. 7 and 8, microinjection of vPhox2 had a
significant effect on protein levels of DBH and NET in the rat LC region (F3,16=7.03, p <
0.001 for DBH; F3,36=3.35, p < 0.05 for NET). Microinjection with vPhox2a or vPhox2b
significantly increased immunoreactivities of DBH in the LC region (52% by vPhox2a,
p<0.01; 27% by vPhox2b, p<0.05). Co-microinjection of vPhox2a and vPhox2b did not
produce synergistic effects on DBH protein levels (increased by 50%, p<0.05; Fig. 7).
Similar to these findings, microinjection of vPhox2a or vPhox2b markedly increased NET
immunoreactivity in the LC by 34% and 41% (both p<0.05), respectively. Likewise, no
synergistic effect was observed for NET immunoreactivity after simultaneous microinjection
of vPhox2a and vPhox2b, compared to those of single microinjections with vPhox2a or
vPhox2b (Fig. 8).
Microinjection of vPhox2 increased protein levels of DBH and NET in the terminal areas of
the LC neurons
In order to assess effects of over-expression of Phox2 genes in the LC on the noradrenergic
phenotype in its terminal areas, protein levels of DBH and NET in the hippocampus and
frontal cortex were measured by Western blotting following microinjection with vPhox2.
Tissue samples were dissected from the same rats that were used for measurement of mRNA
levels described above. Similar to the mRNA measurement mentioned above, there was no
difference for these protein levels between the control and sham groups. As shown in Figs. 9
and 10, microinjection of vPhox2a or vPhox2b markedly affected protein levels of DBH
(F4,28=3.36, p < 0.05, for microinjection of vPhox2a; F4,29=5.40, p < 0.01, for
microinjection of vPhox2b) and NET (F4,34=7.43, p < 0.001, for injection of vPhox2a;
F4,42=6.89, p < 0.001, for injection of vPhox2b) in the hippocampus. Post hoc comparisons
revealed that DBH protein levels were significantly increased in the hippocampus 21 days
(by 71%, p<0.05) after microinjection of vPhox2a, compared with those of the control
group. However, no effect was observed 7 and 14 days after vPhox2a microinjections (Fig.
9A). Microinjection of vPhox2b seemed to have somewhat greater effects on DBH protein
levels in the hippocampus. On days 7, 14 and 21 after microinjection, DBH protein levels
were increased by 57% (p<0.05), 82% (p<0.01) and 59% (p<0.05) respectively (Fig. 9B).
Similarly, 7, 14 and 21 days after microinjection of vPhox2a, NET protein levels in the
hippocampus were increased by 167% (p<0.01), 77% (p<0.05), and 74% (p<0.05),
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respectively (Fig. 10A). On days 7, 14 and 21 after microinjection of vPhox2b, NET protein
levels in the hippocampus were also increased by 40% (p>0.05), 70% (p<0.01) and 63%
(p<0.01; Fig. 10B), compared to those in the control group.
As shown in Fig. 11, microinjection of vPhox2a or vPhox2b significantly affected NET
protein levels in the frontal cortex (F4,33=3.86, p<0.05 for vPhox2a; F4,27=4.22, p<0.01 for
vPhox2b). On days 14 and 21, but not on day 7 after microinjection of vPhox2a, NET
protein levels in the frontal cortex were increased by 33% and 42%, respectively, (both
p<0.05, Fig. 11A). On days 7 and 14, but not on day 21 after microinjection of vPhox2b,
NET protein levels were increased by 57% and 52%, respectively (both p<0.05, Fig. 11B).
Nevertheless, although on days 7, 14 and 21 after microinjection with vPhox2a or vPhox2b,
DBH protein levels in that area were increased by 6.7%, 28.2% and 35.1%, or by 9.5%,
18.6% and 17.1%, respectively, as compared to the control group, all these increases did not
reach the statistical significance (F4,33=1.62, p>0.05 for vPhox2a; F4,29=1.36, p>0.05 for
vPhox2b; data not shown).
We also assessed whether there were synergistic effects of over-expression of Phox2a and
Phox2b on DBH and NET protein levels in the hippocampus and frontal cortex. These rats
were simultaneously microinjected with mixed preparation of vPhox2a and vPhox2b in both
sides of the LC. Co-microinjection with vPhox2a and vPhox2b significantly affected both
DBH and NET in the hippocampus, and NET in the frontal cortex (F4,31=3.08, p<0.05 for
DBH in the hippocampus, Fig. 9C; F4,42=5.76, p<0.01 for NET in the hippocampus, Fig.
10C; F4,31=5.07, p<0.01 for NET in the frontal cortex, Fig. 11C). However, co-
microinjection with vPhox2a and vPhox2b had no additive or synergistic effects on the
protein levels of DBH in the hippocampus, or NET in the hippocampus or frontal cortex,
when compared to microinjection with either vPhox2a or vPhox2b alone. These results were
consistent with measurements of immunofluorescence observed in the LC region after
microinjection with Phox2 (Figs. 7 and 8).
Microinjection of vPhox2 increased neurogenesis in the DG
Whether over-expression of Phox2 in the rat LC and subsequent elevation of DBH could
have downstream postsynaptic effects in the hippocampal DG, a LC neuronal terminal area
in the brain, was evaluated by measuring neurogenesis following vPhox2 microinjection.
BrdU injection was given to rats that were microinjected with vPhox2 for 21 days.
Microinjection of vPhox2 had a substantial effect on the number of BrdU-positive cells in
the DG of the hippocampus, as compared to control rats (F3,273=9.01, p<0.01; Fig. 12 ). The
increase in BrdU-positive cell numbers was significant comparing control and vPhox2b-
microinjected rats (p<0.05), as well as comparing control and co-microinjected (vPhox2a
and vPhox2b) rats (p<0.01). No significant difference was observed comparing control and
vPhox2a-microinjected rats. Co-microinjection with vPhox2a and vPhox2b resulted in a
greater increase in BrdU-positive cells than either vPhox2a or vPhox2b microinjection alone
(p<0.05).
DISCUSSION
In the present study, dual-promoter lentiviral vectors expressing eGFP and rat Phox2a or
Phox2b, i.e. vPhox2a or vPhox2b, were constructed. After in vitro expression testing, these
expressional cassettes were microinjected into the rat LC region to examine effects of
continuous Phox2 over-expression on noradrenergic phenotypes in intact LC neurons of rats.
Intra-LC delivery of the vPhox2 resulted in sustained elevation of Phox2a and Phox2b
mRNA levels. Elevated gene expressions were accompanied by parallel significant increases
in DBH and NET protein levels in the LC and its terminal areas such as the hippocampus
and frontal cortex. To our knowledge, this is the first study of forced over-expression of
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Phox2a and Phox2b in the LC of adult rats. The present study is the extension of our
previous in vitro investigation, in which over-expression with cDNAs of human Phox2 or
shutdown of endogenous Phox2 genes with shRNAs caused a parallel increase or reduction,
respectively, in the expression and function of DBH and NET in SK-N-BE(2)C cells (Fan et
al., 2009). The findings, coupled with a previous report (Card et al., 2010), support the
hypothesis that Phox2a and Phox2b, determinants for development of noradrenergic
phenotypes during embryogenesis, continue to maintain the phenotype of noradrenergic
neurons in adult rat brains and may play a role in homeostasis.
Phox2b expression in the mouse LC has been reported to be transient and shut down at
E11.5 (Pattyn et al., 1997, Pattyn et al., 2000). At birth, only Phox2a expression is detectable
in the LC and subcoeruleus (Tiveron et al., 1996, Pattyn et al., 1997), and expression
continues into adulthood in mice (Tiveron et al., 1996) and rats (Card et al., 2010). Recent
studies show that A5, A6 (LC) and A7 cell groups do not express Phox2b in adult Sprague-
Dawley rats (Kang et al., 2007). However, the present results using in situ hybridization
clearly demonstrate that Phox2b mRNA is detectable in the LC of adult Fischer 344 rats.
Possible explanations for the discrepancy between our results and previous observations
(Pattyn et al., 2000, Kang et al., 2007) include different rat strains and different methods for
measuring Phox2 (in situ hybridization versus immunostaining). It is worthwhile to note that
mRNA levels of Phox2b in the LC of Fischer 344 are much lower (Fig. 4) than those of
Phox2a (Fig. 3B). Nevertheless, the presence of Phox2b gene expression in the LC of adult
Fischer 344 rats and the expression enhancement of DBH and NET after forced expression
of Phox2b in the LC suggest that Phox2b plays a role in maintaining and modulating
noradrenergic phenotypes in the adult brain.
Viral gene delivery systems are powerful tools for the expression of exogenous cDNAs
especially in neuronal cells. Among them, lentiviral vectors remain most promising for the
long-term, stable expression of transgenes in vivo owing to their ability to integrate into the
genome of the dividing and non-dividing host cells (Naldini et al., 1996) after
retrotranscription (Lois et al., 2002, Pfeifer et al., 2002). After lentiviral injection in the rat
brain, the majority of transduced cells are neurons (Naldini et al., 1996). In the present study
we chose lentiviral vectors because of their pantropic nature in the nervous system after in
vivo delivery. Seven days after microinjection of lentiviral cassettes, Phox2a mRNA levels
were increased over two folds and this higher expression level persisted over the next two
weeks, demonstrating efficient transduction and stable expression of Phox2 genes. This time
point and increased range are consistent with previous reports in which lentiviral vector-
induced transduction and stable expression of marker genes were first observed in adult rat
brains (Naldini et al., 1996). Compared to that of Phox2a, however, forced expression of
Phox2b appeared relatively slower. Although there was a modest increase in mRNA levels
of Phox2b on days 7 (about 23%) and 14 (about 20%) after vPhox2b microinjection, a
significant increase of Phox2b mRNA in the LC was observed only 21 days after
microinjection (Fig. 4). Whether the relatively low expression of endogenous Phox2b genes
in the LC accounts for this different transgene pattern, as compared to Phox2a, remains to be
elucidated. Nevertheless, even these modest increments of Phox2b mRNAs still markedly
increased the expression of DBH and NET in the LC and in LC terminal areas. Indeed,
Phox2b has been reported to be the main regulator of the noradrenergic phenotype (Coppola
et al., 2005), as Phox2b not only binds to and transactivates the promoters of these
phenotypes, but also even regulates the expression of Phox2a by directly binding to its 5′
regulatory region (Yang et al., 1998, Adachi et al., 2000, Flora et al., 2001).
Neuronal loss in the LC in brains of the aged subjects and patients suffering from
progressive neurodegenerative diseases such as PD and AD has been well documented
(Mann et al., 1983, Bondareff et al., 1987, Cash et al., 1987, Chan-Palay and Asan, 1989,
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Forstl et al., 1994, Zarow et al., 2003). Dysfunction of the central noradrenergic system
resulting from LC neuronal loss and LC neuron degeneration-induced NE deficiency may
contribute to changes in attention, learning, information processing, and motor function
appearing in aging populations, and also to symptoms such as dementia, memory loss,
depression, anxiety, postural dysfunction observed in PD and AD. However, the causes and
cellular mechanisms of LC neuronal loss in aging and in neurodegenerative diseases are
poorly understood. A number of studies have drawn attention to the involvement of Phox2
genes in these mechanisms, specifically: (1) Phox2a/2b genes are exclusively expressed in
the noradrenergic neurons. The co-localization of Phox2 genes with noradrenergic markers
have been demonstrated in mouse embryos (Pattyn et al., 1999) and neonates (Tiveron et al.,
1996), as well as in the brain of adult rats (Card et al., 2010). Their co-expressional pattern
is especially found in the LC region, as only neurons in this region are noradrenergic and
there are no interneurons there. (2) They are essential and determinant for the generation and
development of noradrenergic neurons during embryogenesis; (3) Phox2a genes are
commonly considered to be persistently present in adult brains; and (4) Phox2a/2b can
directly transactivate the promoters of DBH and NET, both characteristic factors of
noradrenergic neurons. Our previous study demonstrated that reduced Phox2 mRNA levels
in the LC of aged rats was accompanied by parallel reduction of DBH and NET mRNA
levels (Zhu et al., 2005), indicating the possibility of a causal relationship between Phox2
genes and expression of the noradrenergic phenotypes during aging. If so, then delivery of
related transcription factors into the LC of brains to up-regulate the phenotype may be a
strategy to arrest or counteract the neurodegenerative process in aging or degenerative
diseases. The demonstration here that forced over-expression of Phox2 genes in the LC
markedly enhances expression of DBH and NET in the LC and its terminal areas in adult
rats raises the possibility that such an approach could have therapeutic implications for
aging, AD and PD (Costantini et al., 2000) and other disorders where noradrenergic deficits
have been demonstrated. While the essential effects of these transcription factors on the
noradrenergic phenotype during embryogenesis have been well documented (Goridis and
Rohrer, 2002, Howard, 2005, Huber, 2006), their roles in the adult brain need to be
elucidated. Likewise, whether increased noradrenergic gene expression resulted from an
increased noradrenergic neuronal number or an increase NE synthesis in existing neurons is
also an important issue to be addressed.
The mechanisms by which forced over-expression of Phox2 genes in the LC of rats
increases expression of the noradrenergic phenotype remain to be determined. Enhanced
expression may result from a direct transactivation of target genes by these transcription
factors. Multiple cis-elements and homeodomain (HD)-binding sites in the promoter of
DBH and NET genes have been identified (Kim et al., 1998, Yang et al., 1998, Kim et al.,
1999, Kim et al., 2002), and binding of Phox2 to these cis-regulatory elements and HD-
binding sites on promoters to transactivate these target genes have been observed (Tissier-
Seta et al., 1993, Zellmer et al., 1995, Yang et al., 1998, Adachi et al., 2000, Kim et al.,
2002). It is also possible that signal transduction pathways such as cAMP/PKA signaling
may be involved. The activation of the DBH promoter by Phox2a is potentiated by cAMP/
PKA and this effect is mediated by a CRE/AP-1 site, essential for Phox2a-mediated reporter
activity, as well as its potentiating by Hand2 (Swanson et al., 1997, Swanson et al., 2000,
Adachi and Lewis, 2002, Xu et al., 2003). Other transcription factors such as bone
morphogenetic protein (BMPs) (Lo et al., 1999), Mash1 (Hirsch et al., 1998), dHand (Xu et
al., 2003) may also take part in this Phox2-mediated enhancement of noradrenergic
phenotypes.
An important finding in the present study is that over-expression of Phox2 genes in the LC
region increased total number of BrdU-positive cells in the DG area of the hippocampus.
This result demonstrates that transgenic upregulation of Phox2 genes in the LC has
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functional consequences in LC projection areas in adult rats. Generally, in animals killed 24
h after BrdU injection, the BrdU-positive cells in the DG represents the newly generated
cells. As one of the active neurogenesis areas in the adult mammalian brain, the
hippocampal DG receives a dense noradrenergic input from LC neurons. The increased
BrdU-positive cells observed here could be a result of increased NE released from LC
terminals, secondary to a Phox2 over-expression-induced upregulation of noradrenergic
neurons. Supporting this interpretation is evidence of the role of NE in modulating
neurogenesis. For example, NE can enhance proliferation (Popovik and Haynes, 2000) and
plays a crucial role after injury (Kolb and Sutherland, 1992). Administration of desipramine
and reboxetine, the NE reuptake inhibitors which increase synaptic NE availability,
increases neurogenesis in the hippocampus (Malberg et al., 2000, Chen et al., 2006),
presumably as a result of increase NE availability in the synapse. In contrast, depletion of
NE with DSP4, a selective noradrenergic neurotoxin, resulted in a 63% reduction in the
proliferation of DG progenitor cells (Kulkarni et al., 2002). Interestingly, the age-dependent
reduction of noradrenergic innervations of the DG in rats and human is associated with
declining neurongenesis in this area (Kuhn et al., 1996, Gould et al., 1999, Ishida et al.,
2000). In the present study, brain NE levels were not measured and we do not have direct
evidence of increased NE in the synapse. Generally, an increased DBH expression may
increase NE levels as DBH possesses the regulatory effect on NE biosynthesis based on the
literature (Wise et al., 1977, Thomas et al., 1995, Thomas et al., 1998, Schroeder et al.,
2010, Steele et al., 2011). Certainly, an increased NET could simultaneously enhance the
reuptake of NE and thereby reduce NE concentrations in the synapse. However, NET is
regulated by many different mechanisms (Mandela and Ordway, 2006) and an increase in
NET proteins does not necessarily mean that the new protein is expressed on the cell
surface, the only place where it is functional and can affect synaptic NE. Even on the
surface, its activity can also be regulated. Second, our latest findings demonstrate a
significant increase of tyrosine hydroxylase (TH) protein levels, the rate limiting enzyme in
NE biosynthesis, in the brain LC after overexpression of Phox2 genes in these transgenic
rats (Fan and Zhu, 2010), supporting the possibility of increased NE levels in the brain of
these transgenic rats. We plan to measure NE concentrations in rats that are microinjected
with vPhox2a and vPhox2b in future experiments to verify this functional consequence.
In the present study, microinjection with vPhox2 significantly increased NET protein levels
in the frontal cortex (Fig. 11). However, no significant changes were found in DBH protein
levels in the frontal cortex after microinjection at any time period. Currently we do not have
a satisfactory explanation for this discrepancy between protein levels of NET and DBH after
microinjection of vPhox2. One possible cause is that their distribution pattern in the frontal
cortex may be a factor. NET and DBH are exclusively co-expressed in cell bodies of
noradrenergic neuron such as the LC, but not always in the terminal areas (Lorang et al.,
1994, Schroeter et al., 2000). This distributional difference is particularly in cortical regions
where DBH expression levels are lower (Schroeter et al., 2000). Therefore, the effect from
microinjection with vPhox2 on DBH in the frontal cortex may be smaller than on NET,
although DBH expression there still shows a potential enhancement.
The present study demonstrated successful construction of two recombinant lentivirus
vectors containing cDNAs of rat Phox2a or Phox2b. With forced expression of Phox2 genes
after microinjection of these recombinants into the rat LC region, an upregulatory effect of
Phox2a and Phox2b on the expression of NET and DBH in the adult rat brains was
observed. These findings imply that Phox2 genes continue to regulate the phenotype of the
noradrenergic neurons after birth. Future studies should focus on elucidating the sequence of
events leading to the Phox2-induced transactivation of the noradrenergic phenotype, and
ultimately on the potential therapeutic utility of such a strategy for the treatment of aging-
related disorders that demonstrate noradrenergic deficits, such as PD and AD.
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Phox2 genes may regulate the expression of noradrenergic phenotypes after birth. >
Recombinant lentiviral eGFP-Phox2 was microinjected into rat locus coeruleus. >
Overexpression of Phox2 upregulated NET and DBH in adult rat brain. >These findings
may have possibly therapeutic implications for aging, AD and PD.
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Comparison of the amino acid sequences of Phox2a in rat, mouse, and human using
CLUSTAL W. Shaded areas show different amino acids. Numbers on the right refer to the
last amino acid on each line.
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Expression of GFP, Phox2 and DBH in HEK 293FT and PC12 cells infected with
recombinant lentiviral eGFP-Phox2 cDNAs (vPhox2). The expression of the GFP marker in
293FT cells (panel A) showed a gene transduction efficiency of 91% by fluorescence
microscopy and fluorescence-activated cell sorter (FACS) analysis (green cells/total cells ×
100%). Protein levels of Phox2a (panel B), Phox2b (panel C) and DBH (panels D and E)
were measured by Western blotting after PC12 cells were infected with vPhox2a or vPhox2b
(all n=5/group). Con: the control group; 1/32, 1/16, 1/8, 1/4, and 1/2 represents dilutions of
the original viral stock of vPhox2a or vPhox2b. *P<0.05 and ** P<0.01, compared to the
control group.
Fan et al. Page 19














A. Transduction efficiency of vPhox2 in the brain as showed by fluorescence in the LC
region of rats observed under fluorescence microscopy magnified as indicated. Scale bar =
100 μm for all images. B. Expression of Phox2a mRNA levels in rat LC region at different
times after microinjection with vPhox2a in the LC region. Upper panel: Phox2a mRNA
detected by in situ hybridization in the LC of rats (n=6/group). Lower panel: quantitative
analysis of mRNA obtained with emulsion-dipped slides, ** P<0.01, compared to the
control group.
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Expression of Phox2b mRNA levels in rat LC region at different times after microinjection
with vPhox2b in the LC region. Upper panel: Phox2b mRNA detected by in situ
hybridization in the LC of rats (n=6/group). Lower panel: quantitative analysis of mRNA
obtained with emulsion-dipped slides, * P<0.05, compared to the control group.
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Effects of over-expression of Phox2 on DBH mRNA levels in rat LC region, determined at
different times after microinjection with vPhox2a or vPhox2b. Upper panel: DBH mRNA
detected by in situ hybridization in the LC of rats (n=6/group). Lower panel: quantitative
analysis of DBH mRNA obtained with emulsion-dipped slides, * P< 0.05, compared to the
control. C, control; S, sham; 2a/7-21, 3 time points after vPhox2a injections; 2b/7-21, 3 time
points after vPhox2b injections.
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Effects of over-expression of Phox2 on NET mRNA levels in rat LC region, determined at
different times after microinjection with vPhox2 or vPhox2b. Upper panel: NET mRNA
detected by in situ hybridization in the LC of rats (n=6/group). Lower panel: quantitative
analysis of NET mRNA obtained with emulsion-dipped slides, * P<0.05, ** P<0.01,
compared to the control. See Fig. 5 for abbreviations.
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Expression of DBH-immunoreactivity in the LC after microinjection of vPhox2 into the rat
LC region. The top panels are representative micrographs of DBH immunofluorescence in
the LC region of control, vPhox2a-injected, vPhox2b-injected and vPhox2a+vPhox2b
microinjected rats. The bottom panels show measurements of the area fraction of DBH
immunofluorescence in the LC region (n=6/group). * P<0.05, ** P<0.01, compared to the
control.
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Expression of NET-immunoreactivity in the LC region after microinjection of vPhox2 into
the rat LC regions. The top panels are representative micrographs of NET
immunofluorescence in the LC region of control, vPhox2a-injected, vPhox2b-injected and
vPhox2a+vPhox2b injected rats. The bottom panels show measurements of the area fraction
of NET immunofluorescence in the LC regions (n=6/group). * P<0.05, compared to the
control.
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Effects of over-expression of Phox2 on DBH protein levels in rat hippocampus, determined
at different times after microinjection with vPhox2 into the LC region. The upper figure of
each panel show autoradiographs obtained by Western blotting of DBH after microinjection
with vPhox2a (panel A), vPhox2b (panel B), and co-injection (panel C) (all n=6/group). The
lower graph in each panel shows quantitative analysis of band densities. Values of DBH
bands were normalized to those of β-actin probed on the same blot. *P<0.05, ** P<0.01,
compared to the control group. C, control; S, sham; 2a/7-21, 3 time points after vPhox2a
microinjections; 2b/7-21, 3 time points after vPhox2b microinjections. 2a, microinjection
with vPhox2a; 2b, microinjection with vPhox2b; 2a+2b, co-microinjection with vPhox2a
and vPhox2b.
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Effects of over-expression of Phox2 on NET protein levels in rat hippocampus, determined
at different times after microinjection with vPhox2 into the LC region. The upper figure of
each panel show autoradiographs obtained by Western blotting of NET after microinjection
with vPhox2a (panel A), vPhox2b (panel B), and co-microinjection (panel C) (all n=6/
group). The lower graph in each panel shows quantitative analysis of band densities. Values
of NET were normalized to those of β-actin probed on the same blot. *P<0.05, ** P<0.01,
compared to the control group. See Fig. 9 for abbreviations.
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Effects of over-expression of Phox2 on NET protein levels in rat frontal cortex, determined
at different times after microinjection with vPhox2a or vPhox2b into the LC region. The
upper figure of each panel show autoradiographs obtained by Western blotting of NET after
microinjection with vPhox2a (panel A), vPhox2b (panel B), and co-microinjection (panel C)
(all n=6/group). The lower graph in each panel shows quantitative analysis of band densities.
Values of NET were normalized to those of β-actin probed on the same blot. *P<0.05,
compared to the control group. C, control; S, sham; 2a, microinjection with vPhox2a; 2b,
microinjection with vPhox2b; 2a+2b, co-microinjection with vPhox2a and vPhox2b.
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Microinjection of vPhox2 increased the number of BrdU-positive cells in the DG of the
hippocampus. Shown are representative examples of BrdU-positive cells in the DG (upper
panels, Scale bar: 100 μm) and counted BrdU-positive cell numbers (low panel, all n=6/
group). *P<0.05, ** p<0.01, compared to the control group; † p<0.05, compared to the
group microinjected with vPhox2a or vPhox2b. 2a, microinjection with vPhox2a; 2b,
microinjection with vPhox2b; 2a+2b, co-microinjection with vPhox2a and vPhox2b. SGZ:
the subgranular zone (indicated by arrow); GCL: the granule cell layer.
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